|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
D
|
|
INDICATIONS:
|
|
Carcinoma, breast |
|
Ductal Carcinoma in Situ |
| |
|
|
SIDE EFFECTS:
|
|
Confusion |
|
erythema multiforme, bullous pemphigoid, or Stevens-Johnson syndrome |
|
hepatotoxicity |
|
ocular toxicity, including retinopathy, keratopathy, cataracts, and optic neuritis |
|
pulmonary embolism |
|
thrombosis |
|
weakness or sleepiness |
|
Endometrial hyperplasia , endometrial polyps , or endometrial carcinoma |
|
Hot flashes |
|
weight gain |
|
Headache |
|
nausea and/or vomiting, mild |
|
skin rash or dryness |
|
transient local disease flare |
|
Changes in menstrual period |
|
itching in genital area |
|
vaginal discharge |
|
Impotence or decrease in sexual interest |
|
Hair thinning or partial hair loss |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Cataracts or vision disturbances |
|
Hyperlipidemia |
|
Leukopenia |
|
>> Sensitivity to tamoxifen |
|
Thrombocytopenia |
|
|
ADULT DOSE:
|
|
Breast carcinoma-
Node-negative or node-positive: In women-Oral, 10 mg (base) two times a day (in the morning and evening) .
Metastatic: In men and women-Oral, 10 to 20 mg (base) two times a day (in the morning and evening) .
Breast carcinoma (prophylaxis)-
Oral, 20 mg (base) daily for five years.
[Melanoma, malignant] or
[Carcinoma, endometrial] -
Consult medical literature and manufacturer's literature for specific dosages.
Ductal carcinoma in situ (prophylaxis) -
Oral, 20 mg (base) daily for 5 years. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|